Background
Ferumoxytol, an intravenous iron supplement, is commonly used to treat anemia in pregnancy. Ferumoxytol‐enhanced magnetic resonance angiography (Fe‐MRA) is a viable off‐label alternative to gadolinium‐enhanced MRA for assessment of pulmonary embolism (PE) in pregnancy.
Purpose
To describe our clinical experience with Fe‐MRA in pregnant women with suspected PE.
Study type
Retrospective, observational, cohort.
Population
A total of 98 Fe‐MRA exams (consecutive sample) performed in 94 pregnant women.
Field Strength/Sequence
A 1.5 T and 3.0 T, 3D T1‐weighted MRA.
Assessment
After IRB approval including a waiver of informed consent, electronic health records were reviewed retrospectively for all Fe‐MRA exams performed at our institution in pregnant between January, 2017 and March, 2022. The Fe‐MRA protocol included 3D‐MRA for assessment of pulmonary arteries, and T1‐weighted imaging for ancillary findings. Fe‐MRA exam duration was measured from image time stamps. Fe‐MRA exams were reviewed by three cardiovascular imagers using a 4‐point Likert scale for image quality and confidence for PE diagnosis (score 4 = best, 1 = worst), and tabulation of ancillary findings.
Statistical tests
Continuous data are presented as mean ± standard deviation. The overall image quality and confidence score is given as the mean of three readers.
Results
The 98 Fe‐MRA exams were performed in 94 pregnant women (age 30 ± 6, range 19–48 years, gestational week 23 ± 10, range 3–38 weeks), with four undergoing two Fe‐MRA exams during their pregnancy. Median Fe‐MRA exam durration was 8 minutes (interquantile range 6 minutes). Overall image quality score was 3.3 ± 0.9. Confidence score for diagnosing PE was 3.5 ± 0.8. One subject was positive for PE (1/94, 1%); 42 of the 94 (45%) subjects Fe‐MRA had ancillary findings including hydronephrosis or pneumonia.
Conclusion
Ferumoxytol enhanced MRA is a radiation‐ and gadolinium‐free alternative for diagnosis of PE during pregancy.
Evidence Level
4
Technical Efficacy
Stage 5